JP7684519B2 - ヒアルロン酸誘導体、医薬組成物、及び医薬組成物の製造方法 - Google Patents

ヒアルロン酸誘導体、医薬組成物、及び医薬組成物の製造方法 Download PDF

Info

Publication number
JP7684519B2
JP7684519B2 JP2024524929A JP2024524929A JP7684519B2 JP 7684519 B2 JP7684519 B2 JP 7684519B2 JP 2024524929 A JP2024524929 A JP 2024524929A JP 2024524929 A JP2024524929 A JP 2024524929A JP 7684519 B2 JP7684519 B2 JP 7684519B2
Authority
JP
Japan
Prior art keywords
hyaluronic acid
acid derivative
group
pharmaceutical composition
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024524929A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023234376A1 (https=
Inventor
昂平 藪内
貴士 中井
文康 百瀬
洋 珠玖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Corp
Original Assignee
Asahi Kasei Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Corp filed Critical Asahi Kasei Corp
Publication of JPWO2023234376A1 publication Critical patent/JPWO2023234376A1/ja
Priority to JP2025082087A priority Critical patent/JP7818130B2/ja
Application granted granted Critical
Publication of JP7684519B2 publication Critical patent/JP7684519B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024524929A 2022-05-31 2023-05-31 ヒアルロン酸誘導体、医薬組成物、及び医薬組成物の製造方法 Active JP7684519B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025082087A JP7818130B2 (ja) 2022-05-31 2025-05-15 ヒアルロン酸誘導体、医薬組成物、及び医薬組成物の製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022088995 2022-05-31
JP2022088995 2022-05-31
PCT/JP2023/020372 WO2023234376A1 (ja) 2022-05-31 2023-05-31 ヒアルロン酸誘導体、医薬組成物、及び医薬組成物の製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025082087A Division JP7818130B2 (ja) 2022-05-31 2025-05-15 ヒアルロン酸誘導体、医薬組成物、及び医薬組成物の製造方法

Publications (2)

Publication Number Publication Date
JPWO2023234376A1 JPWO2023234376A1 (https=) 2023-12-07
JP7684519B2 true JP7684519B2 (ja) 2025-05-27

Family

ID=89024934

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024524929A Active JP7684519B2 (ja) 2022-05-31 2023-05-31 ヒアルロン酸誘導体、医薬組成物、及び医薬組成物の製造方法
JP2025082087A Active JP7818130B2 (ja) 2022-05-31 2025-05-15 ヒアルロン酸誘導体、医薬組成物、及び医薬組成物の製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025082087A Active JP7818130B2 (ja) 2022-05-31 2025-05-15 ヒアルロン酸誘導体、医薬組成物、及び医薬組成物の製造方法

Country Status (7)

Country Link
US (1) US20250339460A1 (https=)
EP (1) EP4534566A4 (https=)
JP (2) JP7684519B2 (https=)
KR (1) KR20240164786A (https=)
CN (1) CN119301160A (https=)
TW (2) TW202515587A (https=)
WO (1) WO2023234376A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202600172A (zh) * 2024-04-11 2026-01-01 日商旭化成股份有限公司 載體組合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020158771A1 (ja) 2019-01-29 2020-08-06 国立大学法人三重大学 がんワクチン製剤
WO2021157665A1 (ja) 2020-02-07 2021-08-12 旭化成株式会社 ヒアルロン酸誘導体、医薬組成物及びヒアルロン酸誘導体－薬物結合体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759322B2 (en) * 2008-11-05 2014-06-24 National University Corporation Tokyo Medical And Dental University Hyaluronic acid derivative and pharmaceutical composition thereof
WO2014038641A1 (ja) * 2012-09-05 2014-03-13 中外製薬株式会社 アミノ酸およびステリル基が導入されたヒアルロン酸誘導体
ES3044918T3 (en) 2016-03-25 2025-11-27 The Univ Of Osaka Conjugate vaccine targeting disorder-causing in vivo protein
JP2022088995A (ja) 2020-12-03 2022-06-15 株式会社椿本チエイン ワーク保持装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020158771A1 (ja) 2019-01-29 2020-08-06 国立大学法人三重大学 がんワクチン製剤
WO2021157665A1 (ja) 2020-02-07 2021-08-12 旭化成株式会社 ヒアルロン酸誘導体、医薬組成物及びヒアルロン酸誘導体－薬物結合体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
シリカ－疎水化ヒアルロン酸複合ヒドロゲルの合成，日本化学会春季年会講演予稿集(CD-ROM)，2019年
疎水化ヒアルロン酸－リン酸カルシウムハイブリッド微粒子の合成，日本化学会春季年会講演予稿集(CD-ROM)，2016年

Also Published As

Publication number Publication date
TWI870882B (zh) 2025-01-21
JP2025113317A (ja) 2025-08-01
KR20240164786A (ko) 2024-11-20
TW202515587A (zh) 2025-04-16
EP4534566A1 (en) 2025-04-09
EP4534566A4 (en) 2025-09-03
JP7818130B2 (ja) 2026-02-19
CN119301160A (zh) 2025-01-10
JPWO2023234376A1 (https=) 2023-12-07
US20250339460A1 (en) 2025-11-06
WO2023234376A1 (ja) 2023-12-07
TW202402308A (zh) 2024-01-16

Similar Documents

Publication Publication Date Title
US12097252B2 (en) Formulation of a peptide vaccine
Si et al. Intranasal delivery of adjuvant-free peptide nanofibers elicits resident CD8+ T cell responses
JP6041314B2 (ja) がん治療用ワクチン製剤
KR20160113104A (ko) 면역원성 화합물
RS52115B (sr) Nove formulacije tumor-asociranih peptida koji se vezuju za molekule humanog leukocitnog antigena (hla) klase i ili ii za vakcine
JP7818130B2 (ja) ヒアルロン酸誘導体、医薬組成物、及び医薬組成物の製造方法
TWI868812B (zh) 玻尿酸衍生物醫藥組合物及醫藥組合物之製造方法
WO2024041535A1 (zh) 纳米组合物及其制备方法和用途
KR20090112590A (ko) 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 새로운 제형
Yu et al. Conjugation with loxoribine and mannan improves the immunogenicity of Mycobacterium tuberculosis CFP10-TB10. 4 fusion protein
JP2023089973A (ja) ワクチン組成物
WO2024019118A1 (ja) ヒアルロン酸誘導体医薬品組成物及び医薬品組成物
KR20250073419A (ko) 테르페노이드 및 거대분자를 포함하는 신규한 조성물, 및 그의 용도
HK1223290A1 (zh) 结合到人类白细胞抗原(hla)i类或ii类分子上用作疫苗的肿瘤相关肽新制剂
JP5845486B2 (ja) 新規人工設計リポペプチド
HK40013902A (en) Formulation of a peptide vaccine
NZ789530A (en) Formulation of a peptide vaccine
HK1143946A (en) Novel formulations of tumour-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250401

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250515

R150 Certificate of patent or registration of utility model

Ref document number: 7684519

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150